🧬 Neela Patel - Bonum Therapeutics - Part 4 | Transitioning to Seattle Genetics & Business Development | Insights from Roche’s Acquisition | Building a Transformative Oncology Pipeline with Bonum Therapeutics
October 31, 2024
Part 4 of 4:
Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.
Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss.
Part 4 of 4:
Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.
Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss.
Join us this week to hear about:
- Neela’s transition from AbbVie to Seattle Genetics and business development
- Her meeting with Good Therapeutics CEO and how it changed her career trajectory
- Her move to Good Therapeutics as Chief Business Development Officer
- Neela’s experience leading Good through its acquisition by Roche, and the importance of strategic deal structuring
- Her current role as CBO of Bonum Therapeutics and focus on developing cytokine therapies for oncology
Please enjoy Jon’s conversation with Neela Patel!
Subscribe to the podcast: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994
Find Our Guest, Neela Patel, at these links:
Find Our Host, Jon Chee, at these links:
Excedr Socials & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Topics Mentioned:
Bonum Therapeutics: https://bonumtx.com/
Roche: https://www.roche.com/
Seattle Genetics (Pfizer): https://www.seagen.com/who-we-are/history
Vivo Capital: https://vivocapital.com/
Business Development Roles in the Life Sciences: https://www.excedr.com/resources/business-development-in-the-life-sciences
Biotech Startup Support: https://www.excedr.com/resources-category/biotech-startup-support
Buy-side vs. Sell-Side: https://corporatefinanceinstitute.com/resources/career/ma-buy-side-sell-side/
Liquidity Events: https://www.investopedia.com/terms/l/liquidity_event.asp
What Should Investors & Founders Expect From Each Other? https://www.excedr.com/resources/investor-founder-expectations
People Mentioned:
Greg Hageman: https://medicine.utah.edu/faculty/gregory-s-hageman
Diane Hollenbaugh: https://www.linkedin.com/in/diane-hollenbaugh-b826723/
John Mulligan: https://www.linkedin.com/in/john-mulligan-ph-d-5aa5a37/
Timestamps:
00:00 Intro
02:03 Neela’s motivation to join Good Therapeutics, meeting CEO John Mulligan
04:12 Evaluating startup teams and the importance of board alignment
07:01 Building trust with the board and John Mulligan’s approach
09:24 Structuring the Roche deal for streamlined transition
10:46 Good Therapeutics’ culture and team transition to Bonum
13:08 Understanding investor motivations and startup priorities
14:48 Reflections on shifting from buy-side to sell-side
21:46 Bonum’s focus on reducing toxicity in oncology and their clinical pipeline goals
27:37 Shout-outs to career mentors and advice for younger self
31:02 Outro
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so